Newly Validated Q175 Knock-in Model Better Indicator of Huntington’s Disease Condition in Humans
June 8, 2012 - Huntington's disease (HD) is an autosomal neurodegenerative disorder, characterized by severe behavioral, cognitive and motor deficits. Several mouse models, including the R6/2 mouse, which expresses a truncated fragment of mHTT, have been generated to examine the pathogenesis of the disease in an effort to develop novel treatment options. The newly validated Q175 knock-in mouse, however, carries the mutation in its appropriate genomic and protein context, making it, mechanistically, the most true-to-life model of the human condition.
Charles River Discovery Research Services has licensed and validated the Q175 knock-in mouse model, a new tool for researchers investigating the effects of HD therapeutics. This model is a counterpart to the widely used R6/2 mouse line, which demonstrates very fast progression of HD-like symptoms. In contrast, the Q175 mouse develops symptoms early, and with slower progression, allowing ample time to observe the early events triggered by the mutation. Full manifestation of HD-like motor deficits and brain atrophy is apparent in homozygote mice from 3 months and in heterozygote littermates by 4 to 8 months of age. The robustness, gene dose-dependency, progression and early-onset alterations in the Q175 pathogenesis provide researchers with a longer window to detect chronic compound administration effects. Charles River’s mouse efficacy test paradigm includes behavior and cognition, in vivo magnetic resonance imaging (MRI) for brain volumetry and magnetic resonance spectroscopy (MRS) for brain metabolites. Additional testing services are described below.
Behavioral and Cognitive Tests for Huntington’s Disease
For more information about facilitating your Huntington’s disease study with Charles River’s Q175 knock-in model, please contact us at email@example.com.
For more information, contact us at:
*indicates a required field.
The information you provided will be kept confidential.
Immunohistochemical biomarkers can be analyzed using a confocal microscope by having multiple images taken at relatively high magnification, thus allowing us the ability to construct an image of the brain section in good resolution.
Our newly validated ELISpot and FluoroSpot reader services are some of the most sensitive cellular assays available. With this technology. we now offer an even wider range of services to meet vaccine development needs.
juin 24–juin 26
Charles River is once again delighted to be supporting Skin Forum. Our expert scientists will be attending the Annual Meeting and will be happy to meet with you to discuss your dermal product requirements and help you determine how our global capabilities can benefit your development program.
juin 21–juin 25
This five-day meeting draws diverse professionals from around the world to share their breakthroughs in the prevention, diagnosis and treatment of diabetes.
sept. 09–sept. 11
This Charles River sponsored event unites drug development professionals in an interactive setting to discuss the nonclinical development of biologics, including regulatory issues and innovative approaches to problem-solving. The spirit of the meeting fosters extensive information sharing and networking in a casual ambience.
juin 27–juin 27
Charles River offers a wide range of seminars, workshops, and training courses for animal technicians, veterinarians, biologists, and laboratory technicians who work with laboratory animals. For more information about this course, click "view more" below.
This position is responsible for serving as a as a study director (SD), project scientist (PS) and/or principal investigator (PI) in the direction and execution of assigned studies in compliance with GLP regulations as they apply to the conduct of nonclinical research; coordinating all phases of the study planning process with appropriate departments; generating high-quality project plans, protocols, amendments and reports appropriate for assigned studies; reviewing, interpreting, integrating and presenting data on assigned studies; and functioning as contact for the planning and execution of sponsor interaction related to assigned studies, including proposal management and study scheduling, conduct and reporting.
Charles River Laboratories, Inc.